has been cited by the following article(s):
|
[1]
|
Potent anti-tumor immune response and tumor growth inhibition induced by HER2 subdomain fusion protein in a mouse tumor model
Journal of Cancer Research and Clinical Oncology,
2023
DOI:10.1007/s00432-022-04084-0
|
|
|
|
|
[2]
|
Potent anti-tumor immune response and tumor growth inhibition induced by HER2 subdomain fusion protein in a mouse tumor model
Journal of Cancer Research and Clinical Oncology,
2022
DOI:10.1007/s00432-022-04084-0
|
|
|
|
|
[3]
|
Lambda bacteriophage nanoparticles displaying GP2, a HER2/neu derived peptide, induce prophylactic and therapeutic activities against TUBO tumor model in mice
Scientific Reports,
2019
DOI:10.1038/s41598-018-38371-z
|
|
|
|
|
[4]
|
Lambda bacteriophage nanoparticles displaying GP2, a HER2/neu derived peptide, induce prophylactic and therapeutic activities against TUBO tumor model in mice
Scientific Reports,
2019
DOI:10.1038/s41598-018-38371-z
|
|
|
|
|
[5]
|
Lambda bacteriophage nanoparticles displaying GP2, a HER2/neu derived peptide, induce prophylactic and therapeutic activities against TUBO tumor model in mice
Scientific Reports,
2019
DOI:10.1038/s41598-018-38371-z
|
|
|
|
|
[6]
|
The expansion of targetable biomarkers for CAR T cell therapy
Journal of Experimental & Clinical Cancer Research,
2018
DOI:10.1186/s13046-018-0817-0
|
|
|
|
|
[7]
|
Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge
Future Oncology,
2016
DOI:10.2217/fon-2015-0025
|
|
|
|